Adverse outcome pathways - development and potential regulatory application

被引:1
|
作者
Rossi Lima, Thania Rios [1 ]
de Souza, Nathalia Pereira [1 ]
Pereira, Lilian Cristina [1 ,2 ]
Viana de Camargo, Joao Lauro [1 ]
机构
[1] Univ Estadual Paulista, Ctr Evaluat Environm Impact Human Hlth TOXICAM, Dept Pathol, Botucatu, SP, Brazil
[2] Univ Estadual Paulista, Sch Agr Sci, Dept Bioproc & Biotechnol, Botucatu, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
Adverse Outcome Pathways; Hazard Assessment; Mode of Action; Risk Assessment; Regulatory Toxicology; BRADFORD-HILL CONSIDERATIONS; URINARY-BLADDER CARCINOGENS; CONCEPTUAL-FRAMEWORK; SCIENTIFIC CONFIDENCE; 21ST-CENTURY ROADMAP; IPCS FRAMEWORK; MODE; TOXICITY; SUPPORT; RELEVANCE;
D O I
10.22239/2317-269x.01835
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Over the last two decades, chemical safety assessment and regulatory toxicology have progressed from empirical science based on direct observation of apical adverse outcomes in whole organisms to a predictive practice that infers outcomes and risks on the basis of accumulated understanding of toxicological mechanisms and modes of action. Objective: To provide general concepts on how Adverse Outcome Pathways (AOPs) are developed and examples related to skin sensitization, endocrine disruption, and mitochondrial dysfunction. Method: Narrative review based on data of the scientific literature relevant to the theme addressed and on the experience of the authors. Results: An AOP framework provides a systematic approach to organize knowledge about mechanisms of toxicity that may inform analytical domains in regulatory decision-making. AOPs are open structures that may indicate not only data gaps in the understanding of a toxicity process, but also testing procedures that will generate the necessary knowledge to fill those gaps. Every AOP should be continuously refined through the collaborative efforts of the scientific community. Depending on the amount and detail of information that is successively inserted, AOP may progress from the stage of a putative AOP to the stages of qualitative and quantitative AOPs, which are more fit-for-purpose to support regulatory decision-making. Conclusions: Continuous collaboration between AOP developers within the scientific community and the regulatory corps toward the development of this mechanistic structure will support the advancement of toxicological sciences, regardless of its immediate application for regulatory purposes.
引用
收藏
页码:2 / 13
页数:12
相关论文
共 50 条
  • [1] Adverse Outcome Pathways are the future for regulatory toxicology
    Wallace, Heather
    Hines, Ron
    TOXICOLOGY LETTERS, 2018, 295 : S12 - S13
  • [2] Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes
    Patlewicz, Grace
    Simon, Ted W.
    Rowlands, J. Craig
    Budinsky, Robert A.
    Becker, Richard A.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2015, 71 (03) : 463 - 477
  • [3] Applying a systematic approach to the development of evidence-based adverse outcome pathways (AOPs) for regulatory
    Viviani, B.
    Panzarea, M.
    Martino, L.
    Bernardini, E.
    Behring, C.
    Aiassa, E.
    Corsini, E.
    Melcangi, R. C.
    Scanziani, E.
    Terron, A.
    Lanzoni, A.
    TOXICOLOGY LETTERS, 2023, 384 : S75 - S75
  • [4] Application of the adverse outcome pathway conceptual framework for translation of mechanistic data into regulatory decisions: adverse outcome pathways for kidney injury as case study
    Mally, A.
    TOXICOLOGY LETTERS, 2021, 350 : S38 - S38
  • [5] Quantitative Adverse Outcome Pathways and Their Application to Predictive Toxicology
    Conolly, Rory B.
    Ankley, Gerald T.
    Cheng, WanYun
    Mayo, Michael L.
    Miller, David H.
    Perkins, Edward J.
    Villeneuve, Daniel L.
    Watanabe, Karen H.
    ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2017, 51 (08) : 4661 - 4672
  • [6] How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology
    Wittwehr, Clemens
    Aladjov, Hristo
    Ankley, Gerald
    Byrne, Hugh J.
    de Knecht, Joop
    Heinzle, Elmar
    Klambauer, Guenter
    Landesmann, Brigitte
    Luijten, Mirjam
    MacKay, Cameron
    Maxwell, Gavin
    Meek, M. E.
    Paini, Alicia
    Perkins, Edward
    Sobanski, Tomasz
    Villeneuve, Dan
    Waters, Katrina M.
    Whelan, Maurice
    TOXICOLOGICAL SCIENCES, 2017, 155 (02) : 326 - 336
  • [7] Systems toxicology to support development of adverse outcome pathways
    Grafstrom, R. C.
    Hongisto, V.
    Kohonen, P. J.
    Nymark, P.
    TOXICOLOGY LETTERS, 2019, 314 : S25 - S25
  • [8] Adverse outcome pathways
    Bolt, Hermann M.
    ARCHIVES OF TOXICOLOGY, 2017, 91 (12) : 4023 - 4024
  • [9] Adverse outcome pathways
    Hermann M. Bolt
    Archives of Toxicology, 2017, 91 : 4023 - 4024
  • [10] Introducing WikiPathways to link molecular pathways to adverse outcome pathways to support regulatory risk assessment
    Martens, M.
    Willighagen, E.
    Nymark, P.
    Grafstrom, R.
    Burgoon, L. D.
    Aladjov, H. T.
    Andon, F. Torres
    Evelo, C. T.
    TOXICOLOGY LETTERS, 2018, 295 : S227 - S228